
The Mission
Key Opinion Leaders
International
Advisory Board
Initiatives
Discuss a case
Journal Scan
Latest News
Education Hub
Gallery
Editorial Recommendations of the Month
Key articles from high impact journals in last month
August 2021
Ustekinumab 90 mg Every 2 Weeks for the Treatment of Inflammatory Bowel Disease
Storan D, Doherty GA, Cullen G
Published Jul 2021, in the Clinical gastroenterology and hepatology
Assessment of Vedolizumab Disease-Drug-Drug Interaction Potential in Patients With Inflammatory Bowel Diseases
Sun W, Lirio RA, Schneider J, Aubrecht J, Kadali H, Baratta M, Gulati P, Suri A, Lin T, Vasudevan R, Rosario M
Published Jul 2021, in the Clinical Pharmacology in Drug Development
Mental Health Factors Associated With Fatigue in Mexican Patients With Inflammatory Bowel Disease
Fresán Orellana A, Parra Holguín NN, Yamamoto-Furusho JK
Published Aug 2021, in the Journal of clinical gastroenterology.
Diet supporting therapy for inflammatory bowel diseases
Kikut J, Konecka N, Ziętek M, Kulpa D, Szczuko M
Published Aug 2021, in the European journal of nutrition.
Effect of inflammatory bowel disease and related medications on COVID-19 incidence, disease severity, and outcome: the Israeli experience
Richter V, Bermont A, Cohen DL, Broide E, Shirin H
Published Jun 2021, in the European journal of gastroenterology & hepatology
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial
Vermeire S, Su C, Lawendy N, Kobayashi T, Sandborn WJ, Rubin DT, Modesto I, Gardiner S, Kulisek N, Zhang H, Wang W, Panés J
Published Jul 2021, in the Journal of Crohn's & colitis.
Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists
Macaluso FS, Liguori G, Galli M.
Published Jul 2021, in the Gastroenterology.
Dual Targeted Therapy for the Management of Inflammatory Bowel Disease
Haider M, Lashner B
Published Jul 2021, in the Journal of clinical gastroenterology
Antibiotic use differentially affects the risk of antidrug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN
Yuri Gorelik ,Shay Freilich, Shiran Gerassy-Vainberg, Sigal Pressman, Chagit Friss, Alexandera Blatt, Gili Focht, Yiska Loewenberg Weisband, Shira Greenfeld, Revital Kariv, Nathan Lederman, Iris Dotan, Naama Geva-Zatorsky, Yechezkel Kashi, Shai Shlomo Shen-Orr, Yehuda Chowers, On behalf of the IIRN